Entrada Therapeutics, Inc.
Boston, US · 1 known investors
Entrada Therapeutics develops intracellular therapeutics using its EEV Platform to target previously inaccessible disease-causing targets within cells, with a pipeline spanning retinal, neuromuscular, and metabolic diseases including Duchenne muscular dystrophy.
BiotechHealthtechMedical Devices
Investors · 1
In the news
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAprnewswire.com · 2026
- Entrada Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Lossesglobenewswire.com · 2026
- Buy Entrada Therapeutics Stock – TRDA Stock Quote Today & Investment Insights - Public.compublic.com